Epigenetics and triplet-repeat neurological diseases

Frontiers in Neurology

Volumn 6, Issue DEC, 2015, Pages

  Nageshwaran, Sathiji ^a   Festenstein, Richard ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Epigenetics; FRDA; Friedreich's ataxia; HDAC; Heterochromatin; Neurogenetics; Neurology; Triplet repeat

Indexed keywords

FRATAXIN; HETEROCHROMATIN PROTEIN 1;

CELL EXPANSION; CHROMATIN STRUCTURE; DISEASE ASSOCIATION; DNA METHYLATION; DNA STRUCTURE; EPIGENETICS; FRIEDREICH ATAXIA; GENE CONTROL; GENE SILENCING; GENETIC ASSOCIATION; GENETIC SCREENING; HISTONE ACETYLATION; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; IRON CHELATION; KENNEDY DISEASE; MYOTONIC DYSTROPHY; NEUROLOGIC DISEASE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POINT MUTATION; PROMOTER REGION; REVIEW; RNA INTERFERENCE; RNA TRANSCRIPTION; SPINOCEREBELLAR DEGENERATION;

EID: 84954096804     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00262     Document Type: Review

References (98)

1. Allis C, Jenuwein T, Reinberg D. Epigenetics. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press (2007).
2. Deaton A, Bird A. CpG islands and the regulation of transcription. Genes Dev (2011) 25(10):1010-22. doi: 10.1101/gad.2037511.
3. Pelechano V, Steinmetz L. Gene regulation by antisense transcription. Nat Rev Genet (2013) 14(12):880-93. doi:10.1038/nrg3594.
4. Brown C, Hendrich B, Rupert J, Lafrenière R, Xing Y, Lawrence J, et al. The human XIST gene: analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus. Cell (1992) 71(3):527-42. doi:10.1016/0092-8674(92)90520-M.
5. Heitz E. Das Heterochromatin der Moose. Jahrb Wiss Botanik (1928) 69:762.
6. Dillon N, Festenstein R. Unravelling heterochromatin: competition between positive and negative factors regulates accessibility. Trends Genet (2002) 18(5):252-8. doi:10.1016/S0168-9525(02)02648-3.
7. Bulut-Karslioglu A, Perrera V, Scaranaro M, de la Rosa-Velazquez I, van de Nobelen S, Shukeir N. A transcription factor-based mechanism for mouse heterochromatin formation. Nat Struct Mol Biol (2012) 19(10):1023-30. doi:10.1038/nsmb.2382.
8. Harrison I, Dexter D. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease? Pharmacol Ther (2013) 140(1):34-52. doi:10.1016/j.pharmthera.2013.05.010.
9. Dietz K, Casaccia P. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol Res (2010) 62(1):11-7. doi:10.1016/j.phrs.2010.01.011.
10. Bacolla A, Wojciechowska M, Kosmider B, Larson J, Wells R. The involvement of non-B DNA structures in gross chromosomal rearrangements. DNA Repair (2006) 5(9-10):1161-70. doi:10.1016/j.dnarep.2006.05.032.
11. Harding A. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain (1981) 104(3):589-620. doi:10.1093/brain/104.3.589.
12. Schulz J, Pandolfo M. 150 years of Friedreich ataxia: from its discovery to therapy. J Neurochem (2013) 126:1-3. doi:10.1111/jnc.12327.
13. Yandim C, Natisvili T, Festenstein R. Gene regulation and epigenetics in Friedreich's ataxia. J Neurochem (2013) 126:21-42. doi:10.1111/jnc.12254.
14. Pastore A, Puccio H. Frataxin: a protein in search for a function. J Neurochem (2013) 126:43-52. doi:10.1111/jnc.12220.
15. Punga T, Bühler M. Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation. EMBO Mol Med (2010) 2(4):120-9. doi:10.1002/emmm.201000064.
16. Bidichandani S, Ashizawa T, Patel P. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet (1998) 62(1):111-21. doi:10.1086/301680.
17. Chan P, Torres R, Yandim C, Law P, Khadayate S, Mauri M, et al. Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3. Hum Mol Genet (2013) 22(13):2662-75. doi:10.1093/hmg/ddt115.
18. Kumari D, Usdin K. Is Friedreich ataxia an epigenetic disorder? Clin Epigenetics (2012) 4(1):2. doi:10.1186/1868-7083-4-2.
19. Libri V, Yandim C, Athanasopoulos S, Loyse N, Natisvili T, Law P, et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. Lancet. (2014) 384(9942):504-13. doi:10.1016/S0140-6736(14)60382-2.
20. Perlman S. A review of Friedreich ataxia clinical trial results. J Child Neurol (2012) 27(9):1217-22. doi:10.1177/0883073812453872.
21. Rustin P, von Kleist-Retzow J, Chantrel-Groussard K, Sidi D, Munnich A, Rötig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet. (1999) 354(9177):477-9. doi:10.1016/S0140-6736(99)01341-0.
22. Parkinson M, Schulz J, Giunti P. Co-enzyme Q 10 and idebenone use in Friedreich's ataxia. J Neurochem (2013) 126:125-41. doi:10.1111/jnc.12322.
23. Mariotti C, Nachbauer W, Panzeri M, Poewe W, Taroni F, Boesch S. Erythropoietin in Friedreich ataxia. J Neurochem (2013) 126:80-7. doi:10.1111/jnc.12301.
24. Saveliev A, Everett C, Sharpe T, Webster Z, Festenstein R. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature (2003) 422(6934):909-13. doi:10.1038/nature01596.
25. Muller H. Types of visible variations induced by X-rays in Drosophila. J Gen (1930) 22(3):299-334. doi:10.1007/BF02984195.
26. Jenuwein T. Translating the histone code. Science (2001) 293(5532):1074-80. doi:10.1126/science.1063127.
27. Hiragami-Hamada K, Xie S, Saveliev A, Uribe-Lewis S, Pombo A, Festenstein R. The molecular basis for stability of heterochromatin-mediated silencing in mammals. Epigenetics Chromatin (2009) 2(1):14. doi:10.1186/1756-8935-2-14.
28. Wang Z, Zang C, Rosenfeld J, Schones D, Barski A, Cuddapah S, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet (2008) 40(7):897-903. doi:10.1038/ng.154.
29. Kirmizis A. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev (2004) 18(13):1592-605. doi:10.1101/gad.1200204.
30. Festenstein R. Breaking the silence in Friedreich's ataxia. Nat Chem Biol (2006) 2(10):512-3. doi:10.1038/nchembio1006-512.
31. Gottesfeld J. Small molecules affecting transcription in Friedreich ataxia. Pharmacol Ther (2007) 116(2):236-48. doi:10.1016/j.pharmthera.2007.06.014.
32. Gottesfeld J, Rusche J, Pandolfo M. Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia. J Neurochem (2013) 126:147-54. doi:10.1111/jnc.12302.
33. Herman D, Jenssen K, Burnett R, Soragni E, Perlman S, Gottesfeld J. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol (2006) 2(10):551-8. doi:10.1038/nchembio815.
34. Rai M, Soragni E, Jenssen K, Burnett R, Herman D, Coppola G, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One (2008) 3(4):e1958. doi:10.1371/journal.pone.0001958.
35. Ku S, Soragni E, Campau E, Thomas E, Altun G, Laurent L, et al. Friedreich's Ataxia induced pluripotent stem cells model intergenerational GAA·TTC triplet repeat instability. Cell Stem Cell (2010) 7(5):631-7. doi:10.1016/j.stem.2010.09.014.
36. Rai M, Soragni E, Chou C, Barnes G, Jones S, Rusche J, et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One (2010) 5(1):e8825. doi:10.1371/journal.pone.0008825.
37. Xu C, Soragni E, Chou C, Herman D, Plasterer H, Rusche J, et al. Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem Biol (2009) 16(9):980-9. doi:10.1016/j.chembiol.2009.07.010.
38. Soragni E, Miao W, Iudicello M, Jacoby D, De Mercanti S, Clerico M, et al. Epigenetic therapy for Friedreich ataxia. Ann Neurol (2014) 76(4):489-508. doi:10.1002/ana.24260.
39. Evans-Galea M, Carrodus N, Rowley S, Corben L, Tai G, Saffery R, et al. FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann Neurol (2012) 71(4):487-97. doi:10.1002/ana.22671.
40. De Biase I, Chutake Y, Rindler P, Bidichandani S. Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription. PLoS One (2009) 4(11):e7914. doi:10.1371/journal.pone.0007914.
41. Sahdeo S, Scott B, McMackin M, Jasoliya M, Brown B, Wulff H, et al. Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia. Hum Mol Genet (2014) 23(25):6848-62. doi:10.1093/hmg/ddu408.
42. Groh M, Lufino M, Wade-Martins R, Gromak N. R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and Fragile X syndrome. PLoS Genet (2014) 10(5):e1004318. doi:10.1371/journal.pgen.1004318.
43. Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol (2013) 12(8):786-98. doi:10.1016/S1474-4422(13)70125-X.
44. Kremer E, Pritchard M, Lynch M, Yu S, Holman K, Baker E, et al. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science (1991) 252(5013):1711-4. doi:10.1126/science.1675488.
45. Ashley CT, Wilkinson KD, Reines D, Warren ST. FMR1 protein: conserved RNP family domains and selective RNA binding. Science (1993) 262:563. doi:10.1126/science.7692601.
46. Tabolacci E, Moscato U, Zalfa F, Bagni C, Chiurazzi P, Neri G. Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations. Eur J Hum Genet (2008) 16(12):1487-98. doi:10.1038/ejhg.2008.130.
47. Yu S, Pritchard M, Kremer E, Lynch M, Nancarrow J, Baker E, et al. Fragile X genotype characterized by an unstable region of DNA. Science (1991) 252(5009):1179-81. doi:10.1126/science.252.5009.1179.
48. Oberle I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A, et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science (1991) 252(5009):1097-102. doi:10.1126/science.252.5009.1097.
49. Luo S, Robinson J, Reiss A, Migeon B. DNA methylation of the fragile X locus in somatic and germ cells during fetal development: relevance to the fragile X syndrome and X inactivation. Somat Cell Mol Genet (1993) 19(4):393-404. doi:10.1007/BF01232750.
50. Coffee B, Zhang F, Warren ST, Reines D. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet (1999) 22(2):209-209. doi:10.1038/9738.
51. Kumari D, Usdin K. The distribution of repressive histone modifications on silenced FMR1 alleles provides clues to the mechanism of gene silencing in fragile X syndrome. Hum Mol Genet (2010) 19(23):4634-42. doi:10.1093/hmg/ddq394.
52. Colak D, Zaninovic N, Cohen M, Rosenwaks Z, Yang W, Gerhardt J, et al. Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science (2014) 343(6174):1002-5. doi:10.1126/science.1245831.
53. Iwahashi CK, Yasui DH, An HJ, Greco CM, Tassone F, Nannen K, et al. Protein composition of the intranuclear inclusions of FXTAS. Brain (2005) 129(1):256-71. doi:10.1093/brain/awh650.
54. Brook J, McCurrach M, Harley H, Buckler A, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell (1992) 68(4):799-808. doi:10.1016/0092-8674(92)90154-5.
55. Fu Y, Pizzuti A, Fenwick R, King J, Rajnarayan S, Dunne P, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science (1992) 255(5049):1256-8. doi:10.1126/science.1546326.
56. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science (1992) 255(5049):1253-5. doi:10.1126/science.1546325.
57. Harley H, Rundle S, Reardon W, Myring J, Crow S, Harper P, et al. Unstable DNA sequence in myotonic dystrophy. Lancet (1992) 339(8802):1125-8. doi:10.1016/0140-6736(92)90729-M.
58. Lee J, Cooper T. Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans (2009) 37(6):1281. doi:10.1042/BST0371281.
59. Mankodi A, Takahashi M, Jiang H, Beck C, Bowers W, Moxley R, et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell (2002) 10(1):35-44. doi:10.1016/S1097-2765(02)00563-4.
60. Jiang H. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet (2004) 13(24):3079-88. doi:10.1093/hmg/ddh327.
61. Lin X. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet (2006) 15(13):2087-97. doi:10.1093/hmg/ddl132.
62. Kuyumcu-Martinez N, Wang G, Cooper T. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell (2007) 28(1):68-78. doi:10.1016/j.molcel.2007.07.027.
63. Otten A, Tapscott S. Triplet repeat expansion in myotonic dystrophy alters the adjacent chromatin structure. Proc Nat Acad Sci (1995) 92(12):5465-9. doi:10.1073/pnas.92.12.5465.
64. Klesert T, Otten A, Bird T, Tapscott S. Trinucleotide repeat expansion at the myotonic dystrophy locus reduces expression of DMAHP. Nat Genet (1997) 16(4):402-6. doi:10.1038/ng0897-402.
65. Wang Y, Griffith J. Expanded CTG triplet blocks from the myotonic dystrophy gene create the strongest known natural nucleosome positioning elements. Genomics (1995) 25(2):570-3. doi:10.1016/0888-7543(95)80061-P.
66. Klesert T, Cho D, Clark J, Maylie J, Adelman J, Snider L, et al. Mice deficient in Six5 develop cataracts: implications for myotonic dystrophy. Nat Genet (2000) 25(1):105-9. doi:10.1038/75490.
67. Gorbunova V. Genome-wide demethylation destabilizes CTG.CAG trinucleotide repeats in mammalian cells. Hum Mol Genet 13. (2004) 23:2979-89. doi:10.1093/hmg/ddh317.
68. Cho D, Thienes C, Mahoney S, Analau E, Filippova G, Tapscott S. Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell (2005) 20(3):483-9. doi:10.1016/j.molcel.2005.09.002.
69. Lopez Castel A, Nakamori M, Tome S, Chitayat D, Gourdon G, Thornton C, et al. Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues. Hum Mol Genet (2010) 20(1):1-15. doi:10.1093/hmg/ddq427.
70. Ross C, Tabrizi S. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol (2011) 10(1):83-98. doi:10.1016/S1474-4422(10)70245-3.
71. The Huntington's Disease Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell (1993) 72(6):971-83. doi:10.1016/0092-8674(93)90585-E.
72. Andrew S, Paul Goldberg Y, Kremer B, Telenius H, Theilmann J, Adam S, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet (1993) 4(4):398-403. doi:10.1038/ng0893-398.
73. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet (1993) 4(4):387-92. doi:10.1038/ng0893-387.
74. Herndon E, Hladik C, Shang P, Burns D, White C. Intraneuronal polyglutamine aggregates are present in diverse CNS locations in Huntington disease. J Neuropathol Exp Neurol (2007) 66(5):423. doi:10.1097/01.jnen.0000268996.76933.22.
75. Kazantsev A, Preisinger E, Dranovsky A, Goldgaber D, Housman D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Nat Acad Sci (1999) 96(20):11404-9. doi:10.1073/pnas.96.20.11404.
76. Borgonovo J, Troncoso M, Lucas J, Sosa M. Mutant huntingtin affects endocytosis in striatal cells by altering the binding of AP-2 to membranes. Exp Neurol (2013) 241:75-83. doi:10.1016/j.expneurol.2012.11.025.
77. Goula A, Stys A, Chan J, Trottier Y, Festenstein R, Merienne K. Transcription elongation and tissue-specific somatic CAG instability. PLoS Genet (2012) 8(11):e1003051. doi:10.1371/journal.pgen.1003051.
78. Nucifora F Jr. Interference by Huntingtin and Atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science (2001) 291(5512):2423-8. doi:10.1126/science.1056784.
79. Seredenina T, Luthi-Carter R. What have we learned from gene expression profiles in Huntington's disease? Neurobiol Dis (2012) 45(1):83-98. doi:10.1016/j.nbd.2011.07.001.
80. Pallos J, Bodai L, Lukacsovich T, Purcell J, Steffan J, Thompson L, et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet (2008) 17(23):3767-75. doi:10.1093/hmg/ddn273.
81. Bates E. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J Neurosci (2006) 26(10):2830-8. doi:10.1523/JNEUROSCI.3344-05.2006.
82. Hockly E, Richon V, Woodman B, Smith D, Zhou X, Rosa E, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Nat Acad Sci (2003) 100(4):2041-6. doi:10.1073/pnas.0437870100.
83. Thomas E, Coppola G, Desplats P, Tang B, Soragni E, Burnett R, et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Nat Acad Sci (2008) 105(40):15564-9. doi:10.1073/pnas.0804249105.
84. Lee J, Hong Y, Jeon G, Hwang Y, Kim K, Seong K, et al. ATRX induction by mutant huntingtin via Cdx2 modulates heterochromatin condensation and pathology in Huntington's disease. Cell Death Differ (2012) 19(7):1109-16. doi:10.1038/cdd.2011.196.
85. Eustermann S, Yang J, Law M, Amos R, Chapman L, Jelinska C, et al. Combinatorial readout of histone H3 modifications specifies localization of ATRX to heterochromatin. Nat Struct Mol Biol (2011) 18(7):777-82. doi:10.1038/nsmb.2070.
86. Lee J, Hwang Y, Shin J, Lee W, Wie J, Kim K, et al. Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone H3K9me3 impairs Ca2+ signaling in Huntington's disease. Acta Neuropathol (2013) 125(5):727-39. doi:10.1007/s00401-013-1103-z.
87. Vashishtha M, Ng C, Yildirim F, Gipson T, Kratter I, Bodai L, et al. Targeting H3K4 trimethylation in Huntington disease. Proc Nat Acad Sci (2013) 110(32):E3027-36. doi:10.1073/pnas.1311323110.
88. Robertson K. DNA methylation and human disease. Nat Rev Genet (2005) 6(8):597-610. doi:10.1038/nrg1655.
89. Zuccato C. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 293(5529):493-8. doi:10.1126/science.1059581.
90. Villar-Menéndez I, Blanch M, Tyebji S, Pereira-Veiga T, Albasanz J, Martín M, et al. Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease. Neuromolecular Med (2013) 15(2):295-309. doi:10.1007/s12017-013-8219-0.
91. David G, Abbas N, Stevanin G, Dürr A, Yvert G, Cancel G, et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet (1997) 17(1):65-70. doi:10.1038/ng0997-65.
92. Helmlinger D, Hardy S, Abou-Sleymane G, Eberlin A, Bowman A, Gansmüller A, et al. Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol (2006) 4(3):e67. doi:10.1371/journal.pbio.0040067.
93. Palhan V, Chen S, Peng G, Tjernberg A, Gamper A, Fan Y, et al. Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc Nat Acad Sci (2005) 102(24):8472-7. doi:10.1073/pnas.0503505102.
94. McMahon S, Pray-Grant M, Schieltz D, Yates J, Grant P. Polyglutamine-expanded spinocerebellar ataxia-7 protein disrupts normal SAGA and SLIK histone acetyltransferase activity. Proc Nat Acad Sci (2005) 102(24):8478-82. doi:10.1073/pnas.0503493102.
95. Chen I, Lin H, Lee G, Kao S, Chen C, Wu Y, et al. Spinocerebellar ataxia type 8 larger triplet expansion alters histone modification and induces RNA foci. BMC Mol Biol (2009) 10(1):9. doi:10.1186/1471-2199-10-9.
96. Daughters RS, Tuttle DL, Gao W, Ikeda Y, Moseley ML, Ebner TJ, et al. RNA gain-of-function in Spinocerebellar ataxia type 8. PLoS Genet (2009) 5(8):e1000600. doi:10.1371/journal.pgen.1000600.
97. Minamiyama M. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet (2004) 13(11):1183-92. doi:10.1093/hmg/ddh131.
98. Li L, Yu Z, Teng X, Bonini N. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature (2008) 453(7198):1107-11. doi:10.1038/nature06909.